In short
Clinical trials are investigating ZALFERMIN in people with alcohol-related liver disease. These studies look at whether it can help with liver damage and liver function, and they compare it with placebo and other study drugs. The main focus is on safety and how well the treatments work in adults with this condition.
Key points
- ZALFERMIN is being studied in a Phase 2 clinical trial for people with alcohol-related liver disease. The study compares ZALFERMIN-related treatment approaches with placebo and other study drugs. Researchers are looking at liver damage and liver function, with the main outcome being change in Enhanced Liver Fibrosis (ELF). The trial is interventional, which means treatments are assigned by the study team. A total of 287 people were enrolled, and the study status is completed.
Trial overview
This clinical trial studied ZALFERMIN in people with alcohol-related liver disease, a liver condition linked to alcohol use. The study was interventional, which means researchers assigned treatments and then compared outcomes. It was a Phase 2 trial and was marked as completed.
Condition and population studied
The trial focused on adults with alcohol-related liver disease. The study data do not give more detailed entry rules, so the exact participation criteria are not fully listed here. In simple terms, the study looked at people who already had liver problems related to alcohol use.
Treatments being tested
The trial compared ZALFERMIN with other study treatments and with placebo, which is an inactive treatment used for comparison. The listed interventions included cagrilintide, semaglutide, combinations of these drugs, placebo, and ZALFERMIN given by subcutaneous injection, meaning under the skin. The study summary says the goal was to test these treatment options alone and in combination versus placebo for liver damage and function.
Trial phase and design
This was a Phase 2 study, which is a mid-stage trial that looks more closely at whether a treatment may work and keeps checking safety. The study type was interventional, so the research team actively assigned the study treatments instead of only observing people. The enrollment was 287 people, showing a moderate-size trial group for this type of research.
What the trial measures
The main outcome was the change in Enhanced Liver Fibrosis (ELF). ELF is a blood test-based measure used to help estimate liver fibrosis, which means scarring in the liver. By tracking this change, the study aimed to see whether the treatments could improve or affect liver damage and liver function.
What this means for patients
For patients, this trial shows that ZALFERMIN is being explored as part of research for alcohol-related liver disease, not as a routine treatment described in this data. The study looked at whether ZALFERMIN and related treatment combinations could help with liver injury compared with placebo. Because the trial is completed, the next step would be to review the results to understand whether the treatment approach was helpful.